These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7220158)

  • 1. [Electrocardiographic and radiologic evaluation in cardiac involvement in patients with beta-thalassemia major].
    Lo Jacono F; Agnello D; Malizia R; Maltese I; Marasa' R
    Pediatria (Napoli); 1980 Sep; 88(3):385-93. PubMed ID: 7220158
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac complications in homozygous beta-thalassemia.
    Wonke B; Hoffbrand AV; Aldouri MA; Ward SE
    Prog Clin Biol Res; 1989; 309():51-6. PubMed ID: 2780750
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical management of beta-thalassemia.
    Lerner N
    Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
    [No Abstract]   [Full Text] [Related]  

  • 4. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
    Di Gregorio F; Romeo MA; Tasca R; Passaniti G
    Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 6. Causes of hospital admission in children and adults with transfusion-dependent thalassemia in Sardinia, 2000-2015.
    Origa R; Anni F; Mereu L; Follesa I; Campus S; Dessì C; Foschini ML; Leoni G; Moi P; Morittu M; Orecchia V; Perra M; Zappu A; Podda RA
    Ann Hematol; 2017 Jun; 96(6):1041-1042. PubMed ID: 28280993
    [No Abstract]   [Full Text] [Related]  

  • 7. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thalassemic cardiopathy: serial echocardiographic evaluation].
    Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C
    G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980
    [No Abstract]   [Full Text] [Related]  

  • 9. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload.
    Leon MB; Borer JS; Bacharach SL; Green MV; Benz EJ; Griffith P; Nienhuis AW
    N Engl J Med; 1979 Nov; 301(21):1143-8. PubMed ID: 492276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac abnormalities in the thalassaemia syndromes.
    Yee H; Mra R; Nyunt KM
    Southeast Asian J Trop Med Public Health; 1984 Sep; 15(3):414-21. PubMed ID: 6523177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment and treatment of cardiac iron overload in thalassemia.
    Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
    Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Earlier initiation of transfusional and iron chelation therapies in recently born children with transfusion-dependent thalassemia.
    Origa R; Tatti F; Zappu A; Leoni GB; Dessì C; Moi P; Morittu M; Orecchia V; Denotti AR; Pilia MP; Anni F; Perra M; Casini MR; Barella S
    Am J Hematol; 2017 Nov; 92(11):E627-E628. PubMed ID: 28741691
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 14. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics].
    Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F
    Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145
    [No Abstract]   [Full Text] [Related]  

  • 15. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 16. The heart in thalassemia: a comprehensive review.
    Sahasakul Y; Chithiraphan S
    J Med Assoc Thai; 1985 Oct; 68(10):517-27. PubMed ID: 3908610
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality of life and life expectancy in thalassemic patients with complications.
    Gabutti V; Piga A; Sacchetti L; Sandri A; Biginelli M; Saracco P; Ferri M
    Prog Clin Biol Res; 1989; 309():35-41. PubMed ID: 2780748
    [No Abstract]   [Full Text] [Related]  

  • 19. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose.
    Pongtanakul B; Viprakasit V
    Blood Cells Mol Dis; 2013 Aug; 51(2):96-7. PubMed ID: 23566753
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cardiological problems in thalassemia major].
    Mancuso L
    G Ital Cardiol; 1988 Aug; 18(8):665-70. PubMed ID: 3243416
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.